NASDAQ:DCTH Delcath Systems (DCTH) Stock Price, News & Analysis $10.80 -0.30 (-2.70%) Closing price 04:00 PM EasternExtended Trading$10.71 -0.09 (-0.83%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Delcath Systems Stock (NASDAQ:DCTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Delcath Systems alerts:Sign Up Key Stats Today's Range$10.72▼$11.4050-Day Range$10.01▼$11.7552-Week Range$8.08▼$18.23Volume822,507 shsAverage Volume585,916 shsMarket Capitalization$377.78 millionP/E Ratio216.00Dividend YieldN/APrice Target$24.50Consensus RatingModerate Buy Company Overview Delcath Systems, Inc. is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma. Delcath’s approach aims to improve tumor response rates and extend progression-free survival for patients with limited treatment options. The Hepatic CHEMOSAT® Delivery System comprises specialized catheters, an extracorporeal filtration system and an isolation balloon that together isolate the liver’s vasculature, deliver high-dose chemotherapy and filter the returned blood before it reenters the patient’s systemic circulation. Delcath has achieved CE Mark approval in Europe for the treatment of unresectable liver tumors and is advancing its clinical development program in the United States, where it has completed pivotal trials assessing safety and efficacy in patients with ocular melanoma metastases in the liver. The company also continues to explore expanded indications and next-generation applications of its chemosaturation platform. Headquartered in New York, Delcath Systems operates in key oncology markets across North America and Europe, collaborating with leading cancer centers and interventional radiology departments. The organization is guided by a management team and board of directors with experience in medical device commercialization, oncology drug development and regulatory affairs. Delcath remains committed to advancing targeted regional therapies that address unmet needs in the treatment of liver tumors and improving patient outcomes through innovation and rigorous clinical investigation.AI Generated. May Contain Errors. Read More Delcath Systems Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreDCTH MarketRank™: Delcath Systems scored higher than 55% of companies evaluated by MarketBeat, and ranked 497th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingDelcath Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialDelcath Systems has a consensus price target of $24.50, representing about 127.4% upside from its current price of $10.78.Amount of Analyst CoverageDelcath Systems has only been the subject of 2 research reports in the past 90 days.Read more about Delcath Systems' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Delcath Systems are expected to grow in the coming year, from ($0.79) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Delcath Systems is 215.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 234.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Delcath Systems is 215.70, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 85.70.Price to Book Value per Share RatioDelcath Systems has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Delcath Systems' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.15% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Delcath Systems has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDelcath Systems does not currently pay a dividend.Dividend GrowthDelcath Systems does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.15% of the outstanding shares of Delcath Systems have been sold short.Short Interest Ratio / Days to CoverDelcath Systems has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Delcath Systems has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.60 News SentimentDelcath Systems has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Delcath Systems this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 3 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Delcath Systems insiders have not sold or bought any company stock.Percentage Held by Insiders17.94% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Delcath Systems' insider trading history. Receive DCTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCTH Stock News HeadlinesDelcath Systems, Inc. (NASDAQ:DCTH) Receives $24.50 Average Target Price from BrokeragesOctober 6 at 3:08 AM | americanbankingnews.comDelcath Systems (NASDAQ:DCTH) Upgraded at Wall Street ZenOctober 5 at 3:19 AM | americanbankingnews.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 6 at 2:00 AM | StockEarnings (Ad)Craig-Hallum Remains a Buy on Delcath Systems (DCTH)October 4 at 6:37 PM | theglobeandmail.comDelcath Systems announces investigator-initiated CHOPIN Phase 2 presentationSeptember 22, 2025 | msn.comDelcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 CongressSeptember 22, 2025 | businesswire.comDelcath Systems management to meet with Craig-HallumSeptember 17, 2025 | msn.comDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | businesswire.comSee More Headlines DCTH Stock Analysis - Frequently Asked Questions How have DCTH shares performed this year? Delcath Systems' stock was trading at $12.04 at the beginning of the year. Since then, DCTH shares have decreased by 10.5% and is now trading at $10.7750. How were Delcath Systems' earnings last quarter? Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Wednesday, August, 6th. The company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. The firm earned $24.16 million during the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a net margin of 3.18% and a trailing twelve-month return on equity of 6.91%. Read the conference call transcript. When did Delcath Systems' stock split? Delcath Systems's stock reverse split on Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Delcath Systems? Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Delcath Systems own? Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC). Company Calendar Last Earnings8/06/2025Today10/06/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:DCTH CIK872912 Webdelcath.com Phone212-489-2100Fax212-489-2102Employees60Year Founded1988Price Target and Rating Average Price Target for Delcath Systems$24.50 High Price Target$31.00 Low Price Target$21.00 Potential Upside/Downside+118.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$0.05 Trailing P/E Ratio223.40 Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.39 million Net Margins3.18% Pretax Margin4.18% Return on Equity6.91% Return on Assets5.80% Debt Debt-to-Equity RatioN/A Current Ratio10.88 Quick Ratio9.87 Sales & Book Value Annual Sales$37.21 million Price / Sales10.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.15 per share Price / Book5.23Miscellaneous Outstanding Shares34,980,000Free Float28,705,000Market Cap$393.07 million OptionableOptionable Beta0.84 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:DCTH) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.